Avalglucosidase alfa

艾夫糖苷酶 α

Report date: 2023/10/18 16:22:35

Base Information

Drug NameAvalglucosidase alfa
Drug Alias Nameavalglucosidase alfa-ngptavalglucosidasum alfaNeo-recombinant human acid alpha-glucosidaseNeo-rhGAA enzyme therapyNexviazyme +[11] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionGlycogen metabolizersAlpha glucosidase replacementsInsulin-like growth factor II receptor agonists
TargetsGlycogenInsulin-like growth factor II receptor
Therapy Area/IndicationsGlycogen Storage Disease Type II
Global Approved IndicationsGlycogen Storage Disease Type II
Approved Indications in ChinaGlycogen Storage Disease Type II
Original Approved Country/TerritoryUnited States
Original Approved Date2021/08/06
Country/TerritoryCzechiaBelgiumCanada +[27] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenzyme Corp
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis GroupeSanofi BVSanofi +[5] 
Inactive CompaniesGenzyme Ireland LtdSanofi Us Services IncSanofi-Aventis Recherche & Developpement
Active IndicationsGlycogen Storage Disease Type II
Inactive IndicationsN/A

Other Information

ATC CodeA16AB07
Related LinksDrugBankKEGG